Diversion device to increase cerebral blood flow

• US 20060058833A1
• Filed: 09/10/2004
• Published: 03/16/2006
• Est. Priority Date: 09/10/2004
• Status: Active Grant

• Current Assignee: Stryker European Operations Holdings, LLC (Stryker Corporation)
• Original Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Inventors: VanCamp, Daniel, Nielson, Eric D.
• Granted Patent: US 7,927,346 B2
• Time in Patent Office: Days
• US Class Current: 606/200
• CPC Class Codes: A61B 17/12022 Occluding by internal devices, e.g. balloons or releasable wires plugging an opening in the wall of an organ A61B17/0057; occluders for the cervical canal A61F6/146; vas deferens occluders A61F6/20
• CPC Class Codes: A61B 17/12036 partial occlusion
• CPC Class Codes: A61B 17/12109 in a blood vessel
• CPC Class Codes: A61B 17/12136 Balloons
• CPC Class Codes: A61B 17/12172 having a pre-set deployed three-dimensional shape methods of manufacturing A61B2017/00526
• CPC Class Codes: A61B 2017/00004 (bio)absorbable, (bio)resorbable, resorptive for implantable prostheses A61F2210/0004
• CPC Class Codes: A61B 2017/00243 cardiac
• CPC Class Codes: A61B 2017/00575 for closure at remote site, e.g. closing atrial septum defects
• CPC Class Codes: A61B 2017/00579 Barbed implements
• CPC Class Codes: A61B 2017/00592 Elastic or resilient implements
• CPC Class Codes: A61B 2017/00597 Implements comprising a membrane
• CPC Class Codes: A61B 2017/00615 Implements with an occluder on one side of the opening and holding means therefor on the other

Abstract

Methods and devices provide for temporary partial aortic occlusion to achieve diversion of blood flow to the brain in patients suffering from cerebral ischemia. The device includes an expandable frame and membrane that is inserted into the aorta to partially occlude blood flow.

Claims

1. A partial aortic occlusion device comprising:

an expandable frame having a first portion and a second portion;

a membrane mounted on the first portion of the frame, the membrane having an outer region and an inner region, the membrane having an opening in the inner region, wherein the membrane is biodegradable;

wherein during use, the expandable frame expands to conform to the aorta and the membrane at least partially occludes the aorta thereby increasing cerebral perfusion.

2. The partial aortic occlusion device of claim 1, wherein the frame includes one or more anchors configured to removably attach the device to a wall of the aorta.

3. The partial aortic occlusion device of claim 1, wherein the expandable frame is made of super elastic material.

4. The partial aortic occlusion device of claim 1, wherein the expandable frame includes at least two struts, the struts spaced apart in the first portion of the frame and connected in the second portion of the frame.

5. The partial aortic occlusion device of claim 4, wherein at least two struts include one or more anchors configured to removably attach the device to a wall of the aorta.

6. The partial aortic occlusion device of claim 1, wherein the expandable frame is a mesh tube.

7. The partial aortic occlusion device of claim 1, wherein the frame has at least one opening in the second portion, and the opening in the second portion and the opening in the membrane are sized to receive a catheter.

8. The partial aortic occlusion device of claim 1, wherein the membrane is at least partially permeable to blood.

9. The partial aortic occlusion device of claim 1, wherein the membrane has two or more openings.

10. A method for temporarily increasing cerebral blood flow in a patient, comprising the steps of:

inserting an expandable filter device into the aorta; and

expanding the filter device to partially occlude the aorta and increase cerebral blood flow;

wherein the filter device includes a membrane covering less than all of an upstream end of the filter device.

11. The method of claim 10, wherein the membrane is biodegradable.

12. The method of claim 11, wherein the membrane biodegrades upon contact with an enzymatic agent, the method further comprising a step of injecting an enzymatic agent to degrade the membrane after the patient'"'"'s cerebral blood flow returns to a substantially normal level.

13. The method of claim 11, wherein the membrane biodegrades when irradiated;

the method further comprising a step of irradiating the membrane after the patient'"'"'s cerebral blood flow returns to a substantially normal level.

14. The method of claim 10, wherein the filter device is inserted in the aorta above the renal arteries.

15. The method of claim 10, wherein the filter device is inserted below the common carotid artery and braciocephalic trunk.

16. The method of claim 10, wherein the filter device is inserted in the celiac trunk.

17. The method of claim 11, further comprising a step of removing the filter device after the membrane biodegrades.

18. The method of claim 10, wherein the filter device includes a downstream end configured to trap embolisms.

19. The method of claim 18, wherein the membrane has an opening substantially centrally located over the upstream end of the filter device.

20. The method of claim 19, wherein the opening in the membrane is sized to receive a catheter and the downstream end of the device has one or more opening sized to receive a catheter;

such that a catheter can traverse the filter device to provide access to arteries and organs upstream of the filter device.

21. The method of claim 10, wherein the filter device is coated with a non-thrombogenic agent.

22. The method of claim 10, further comprising a step of administering a CO₂/O₂ mixture to the patient.